CV earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -6.58. Updated 2026-07-23.
CapsoVision (CV) Research Hub
CapsoVision (CV) trades on NASDAQ, US in the Healthcare (Medical - Specialties) sector. As of 2026-09-11, shares last closed at 6.6 USD (+3.61%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.58, market cap 0.35B. This hub links to the full technical, earnings and options research available for CV.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Specialties) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.6 USD (+3.61%) |
| 52-week range | 5.62 USD – 7.62 USD |
| Trend regime | Range |
| 14-day RSI | 40.2 (Bearish) |
| Trailing P/E | -6.58 |
| Market cap | 0.35B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for CV
Covered Call on CV: how it works, illustrative setup around the real 6.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CV: how it works, illustrative setup around the real 6.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CV: how it works, illustrative setup around the real 6.6 USD price, max profit/loss, breakeven and when to use it. Educational.
CV technical analysis: range, last 6.6 USD, RSI 40.2, 52w range 5.62 USD–7.62 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CV in?
CapsoVision (CV) is classified under Healthcare (Medical - Specialties), listed on NASDAQ, US.
Is CV in an uptrend or downtrend?
As of 2026-09-11, CV is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CV's trailing P/E ratio?
CV's trailing P/E is -6.58, with a market cap of 0.35B. See the earnings research page for full valuation detail.
When does CV next report earnings?
CV is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.13 USD.